Development of Temporal Dose-Weighted Positron Emission Tomography Metabolic Imaging Biomarkers (PET MIBs) of Radiation-Related Parotid Glands Injury in Oropharyngeal Cancer Patients

2018 ◽  
Vol 102 (3) ◽  
pp. e240-e241
Author(s):  
H. Elhalawani ◽  
S. Volpe ◽  
C.E. Cardenas ◽  
S. Barua ◽  
C. Rock ◽  
...  
2020 ◽  
Author(s):  
Hesham Elhalawani ◽  
Carlos E. Cardenas ◽  
Stefania Volpe ◽  
Souptik Barua ◽  
Sonja Stieb ◽  
...  

Purpose Head and neck cancers (HNC) radiotherapy (RT) is associated with inevitable injury to parotid glands and subsequent xerostomia. We investigated the utility of standardized uptake values (SUV) derived from routinely performed 18-fluorodeoxygluocose positron-emission tomography (18FDG-PET) to develop metabolic imaging biomarkers (MIBs) of RT-related parotid injury. Methods Data for oropharyngeal cancer (OPC) patients treated with RT at our institution between 2005-2015 with available planning computed tomography (CT), dose grid, pre- & first post-RT 18FDG-PET-CT scans, and physician-reported xerostomia assessment at 3-6 months post-RT (Xero 3-6ms) per CTCAE, was retrieved, following an IRB approval. A CT-CT deformable image co-registration followed by voxel-by-voxel resampling of pre & post-RT 18FDG activity and dose grid were performed. Ipsilateral (Ipsi) and contralateral (contra) parotid glands were sub-segmented based on the received dose in 5 Gy increments, i.e. 0-5 Gy, 5-10 Gy sub-volumes, etc. Median and dose-weighted SUV were extracted from whole parotid volumes and sub-volumes on pre- & post-RT PET scans, using in-house code that runs on MATLAB. Wilcoxon signed-rank and Kruskal-Wallis tests were used to test differences pre- and post-RT. Results 432 parotid glands, belonging to 108 OPC patients treated with RT, were sub-segmented & analyzed. Xero 3-6ms was reported as: non-severe (78.7%) and severe (21.3%). SUV- median values were significantly reduced post-RT, irrespective of laterality (p=0.02). A similar pattern was observed in parotid sub-volumes, especially ipsi parotid gland sub-volumes receiving doses 10-50 Gy (p<0.05). A Kruskal-Wallis test showed a significantly higher mean planned RT dose in the contra parotid in the patients with more severe Xero 3-6mo (p= 0.03). Multiple logistic regression showed a combined clinical-dosimetric-metabolic imaging model could predict the severity of Xero 3-6mo; AUC=0.78 (95%CI:0.66-0.85;p<0.0001) Conclusion We sought to quantify pre- and post-RT 18FDG-PET metrics of parotid glands in patients with OPC. Temporal dynamics of PET-derived metrics can potentially serve as MIBs of RT-related xerostomia in concert with clinical and dosimetric variables. Keywords: Xerostomia; FDG-PET; radiotherapy; imaging biomarkers; predictive model; head and neck cancer


2011 ◽  
Vol 17 (14) ◽  
pp. 4814-4824 ◽  
Author(s):  
Astrid A.M. van der Veldt ◽  
Mark Lubberink ◽  
Henri N. Greuter ◽  
Emile F.I. Comans ◽  
Gerarda J.M. Herder ◽  
...  

Author(s):  
Ruiqing Ni

Animal models of Alzheimer&rsquo;s disease amyloidosis that recapitulate cerebral amyloid-beta pathology have been widely used in preclinical research, and have greatly enabled the mechanistic understanding of Alzheimer&rsquo;s disease and the development of therapeutics. Comprehensive deep phenotyping of the pathophysiological and biochemical features in these animal models are essential. Recent advances in positron emission tomography have allowed the non-invasive visualization of the alterations in the brain of animal models as well as in patients with Alzheimer&rsquo;s disease, These tools have facilitated our understanding of disease mechanisms, and provided longitudinal monitoring of treatment effect in animal models of Alzheimer&rsquo;s disease amyloidosis. In this review, we focus on recent positron emission tomography studies of cerebral amyloid-beta accumulation, hypoglucose metabolism, synaptic and neurotransmitter receptor deficits (cholinergic and glutamatergic system), blood-brain barrier impairment and neuroinflammation (microgliosis and astrocytosis) in animal models of Alzheimer&rsquo;s disease amyloidosis. We further propose the emerging targets and tracers for reflecting the pathophysiological changes, and discuss outstanding challenges in disease animal models and future outlook in on-chip characterization of imaging biomarkers towards clinical translation.


Sign in / Sign up

Export Citation Format

Share Document